Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Reporting Period: Quarter ended March 31, 2026
Business Overview: A clinical-stage life science company developing Gemini, a proprietary TLR4 agonist formulation. Current product candidates include GEM-AKI (acute kidney injury) and GEM-CKD (chronic kidney disease). The company has no revenue and is focused on research and development.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,009,051) | $(2,051,085) |
| Net Loss Attributable to Common Stockholders | $(8,690,667) | $(2,051,085) |
| Net Loss Per Share (Basic & Diluted) | $(2.71) | $(25.34) |
| Cash and Cash Equivalents (End of Period) | $14,113,415 | $3,704,611 |
| Total Assets | $15,044,282 | $11,582,924 |
| Total Liabilities | $2,055,329 | $2,721,929 |
| Stockholders' Equity | $12,988,953 | $8,860,995 |
| Accumulated Deficit | $(52,428,338) | $(49,419,287) |
Cash Flow Summary (Q1 2026):
- Operating Cash Flow: $(3,214,851)
- Investing Cash Flow: $(71,879)
- Financing Cash Flow: $6,699,814 (primarily from warrant exercises)
Material Changes vs. Prior Period
- Operating Expenses: Increased by $997,513 (48%) to $3.09 million.
- Research & Development: Increased $518,031 to $1.38 million, driven by GEM-AKI manufacturing expenses ($314k) and personnel costs.
- General & Administrative: Increased $479,482 to $1.72 million, due to higher personnel costs and professional fees.
- Capital Structure: Significant equity activity occurred in Q1 2026.
- Warrant Inducement: The company executed a Class I Warrant Inducement, raising approximately $6.7 million in net proceeds through the cash exercise of 2.14 million warrants at a reduced price of $3.44/share.
- Deemed Dividends: A non-cash deemed dividend of $5.68 million was recorded due to exercise price reductions on various warrant classes triggered by the inducement.
- Reverse Stock Split: A 1-for-4 reverse stock split was effected on January 28, 2026.
- Liquidity: Cash balance increased by $3.41 million, primarily due to financing activities, offsetting the operating burn.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Current cash ($14.1 million) is not expected to sustain operations for one year from the filing date. Additional capital is required to fund R&D and operations.
- Future Funding: The company plans to seek additional funding through public or private equity or debt financings. Failure to secure funding could result in delays or elimination of R&D programs.
- Revenue Outlook: The company has never generated revenue and does not expect to do so for at least several years, if ever, pending regulatory approval of product candidates.
- Risks:
- Potential delisting from Nasdaq if market value or equity requirements are not met.
- Dilution of existing shareholders in future financing rounds.
- Uncertainty regarding clinical trial success and regulatory approval timelines.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure regarding the one-year sustainability of current cash reserves.
- Dilution Impact: Review the terms of the Class I and Class J warrants issued in the inducement and the remaining outstanding warrant pool (approx. 8.9 million shares underlying warrants) to assess future dilution.
- Deemed Dividend Accounting: Confirm the impact of the $5.68 million deemed dividend on the accumulated deficit and net loss attributable to common stockholders.
- Listing Compliance: Monitor Nasdaq compliance status, specifically regarding minimum bid price and market value of publicly held shares, given the recent reverse splits and capital raises.
- R&D Milestones: Track progress on GEM-AKI and GEM-CKD clinical trials to assess the timeline for potential revenue generation.